Study of ARC-520 in Patient With Chronic Hepatitis B Virus

Inclusion Criteria: * Male or female, 18 to 65 years of age * Written informed consent * No clinically significant abnormalities at screening/pre-dose 12-lead ECG assessment * No abnormal finding of clinical relevance * Diagnosis of immune active chronic HBV infection * \> 6 months of continuous treatment with daily, oral entecavir or tenofovir Exclusion Criteria: * Pregnant or lactating * Acute signs of hepatitis/other infection within 4 weeks of screening * Antiviral therapy other than entecavir or tenofovir within 3 months of screening * Prior treatment with interferon or a toll receptor agonist in last 12 months * Use of anticoagulants, corticosteroids, immunomodulators, or immunosuppressants * Use of dietary and/or herbal supplements that can interfere with liver metabolism * Use of any drugs known to induce or inhibit hepatic drug metabolism * Use of prescription medication or over-the-counter products * Depot injection/implant of any drug except birth control. * Known diagnosis of diabetes mellitus. * History of autoimmune disease * Human immunodeficiency virus (HIV) infection * Sero-positive for HCV, and/or history of delta virus hepatitis * Hypertension: blood pressure \> 150/100 mmHg * History of cardiac rhythm disturbances * Family history of congenital long QT syndrome/unexplained sudden cardiac death * Symptomatic heart failure, unstable angina, myocardial infarction, severe cardiovascular disease * History of malignancy, except adequately treated basal cell carcinoma, squamous cell skin cancer, superficial bladder tumors, in situ cervical cancer * Major surgery within 3 months of screening * History of alcohol and/or drug abuse \< 12 months from screening * Regularly uses alcohol within past 6 months (ie, more than 14 units of alcohol per week) * Evidence of acute inflammation, sepsis, or hemolysis * Diagnosed with a significant psychiatric disorder * Use of drugs of abuse * History of allergy to bee venom * Use of investigational agents/devices within 30 days * Current participation in an investigational study * Clinically significant gastrointestinal pathology, unresolved gastrointestinal symptoms, liver or kidney disease * History/presence of Gilbert's syndrome, conditions that interfere with absorption, distribution, metabolism, excretion of drugs * Presence of cholangitis, cholecystitis, cholestasis, or duct obstruction * Clinically significant history/presence of uncontrolled systemic disease * Donated blood (500 mL) within 7 days prior to study treatment administration * History of fever within 2 weeks of screening * Immunization/planned immunization with live attenuated vaccine except influenza vaccine * Excessive exercise/physical activity within 7 days of screening/enrolment or during study * History of coagulopathy or stroke within past 6 months, and/or concurrent anticoagulants